(Q38465267)

3 September 2017

1 reference

title

Nasal and pulmonary vaccine delivery using particulate carriers (English)

1 reference

3 September 2017

Yimei Jia

1

1 reference

3 September 2017

Lakshmi Krishnan

series ordinal

2

1 reference

3 September 2017

Abdelwahab Omri

series ordinal

3

1 reference

3 September 2017

language of work or name

English

0 references

publication date

8 May 2015

1 reference

Expert Opinion on Drug Delivery

3 September 2017

published in

1 reference

3 September 2017

volume

12

1 reference

3 September 2017

issue

6

1 reference

3 September 2017

page(s)

993-1008

1 reference

Characterization of viral agents causing acute respiratory infection in a San Francisco University Medical Center Clinic during the influenza season

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Epidemiology and unique aspects of aging and infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Vaccines against mucosal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Mucosal vaccines: the promise and the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Nanocarriers targeting dendritic cells for pulmonary vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Non-invasive systemic drug delivery: developability considerations for alternate routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Airway epithelial cell signaling in response to bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Innate immunity in the lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Production of Chemotactic Factor(s) by in vivo Cultured Human Alveolar Macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

The airway epithelium: soldier in the fight against respiratory viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Pathogenic potential of interferon αβ in acute influenza infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Cell-mediated adaptive immune defense of the lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Distinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Facilitation of Th1-mediated immune response by prostaglandin E receptor EP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Production of interferon-gamma by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Antiviral CD8+ T cell effector activities in situ are regulated by target cell type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Role of upper and lower respiratory tract immunity in resistance to Mycoplasma respiratory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

The upper and lower respiratory tracts differ in their requirement of IFN-gamma and IL-4 in controlling respiratory mycoplasma infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Vaccines: from empirical development to rational design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Nanoparticulate adjuvants and delivery systems for allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Mechanisms of action of adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

PLA-PEG particles as nasal protein carriers: the influence of the particle size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Pathogen recognition and development of particulate vaccines: does size matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Vaccine adjuvants revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Mucosal immunisation: adjuvants and delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Pulmonary vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Recent advances in mucosal vaccines and adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Effects of different CpG oligodeoxynucleotides with inactivated avian H5N1 influenza virus on mucosal immunity of chickens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Vaccine delivery: lipid-based delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Importance of physical association between antigen and liposomes in liposomes adjuvanticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Challenges in mucosal vaccination of cattle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Iscom is an efficient mucosal delivery system for Mycoplasma mycoides subsp. mycoides (MmmSC) antigens inducing high mucosal and systemic antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Archaeosome adjuvants: immunological capabilities and mechanism(s) of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Intranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Virus-like particles in vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Norwalk virus-like particles as vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

M2e-based universal influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Nanoparticles for nasal vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Formulation aspects of biodegradable polymeric microspheres for antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Chitosan as a novel nasal delivery system for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Design of biodegradable particles for protein delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Biodegradable nanoparticles modified by branched polyethylenimine for plasmid DNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

The possible "proton sponge " effect of polyethylenimine (PEI) does not include change in lysosomal pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

PEI - a potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell response and FasL-mediated cell death in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Effect of chitosan on epithelial permeability and structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Delivery technologies for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

New developments in dry powder pulmonary vaccine delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Immunization by a bacterial aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

21 January 2018

Nanoparticle vaccines

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Nasal vaccination using live bacterial vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Technologies for enhanced efficacy of DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1044435

10.1517/17425247.2015.1044435

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference